Grace Therapeutics (GRCE) Shares Outstanding (2017 - 2026)

Grace Therapeutics has reported Shares Outstanding (Entity) for 10 years, with the latest figure at $16.0 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 16.81% year-over-year to $16.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.0 million (up 16.81% YoY) and the FY2026 annual result came in at $16.0 million, up 16.81% from the prior year.
• Shares Outstanding (Entity) climbed to $16.0 million in Q1 2026 per GRCE's latest filing, from $15.5 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $16.0 million in Q1 2026 and troughed at $6.1 million in Q1 2022.
• A 5-year average of $10.2 million and a median of $9.4 million in 2023 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) jumped 148.46% in 2022, then climbed 0.27% in 2023.
• Over 5 years, Shares Outstanding (Entity) stood at $7.4 million in 2022, then gained by 26.41% to $9.4 million in 2023, then rose by 7.88% to $10.1 million in 2024, then soared by 52.61% to $15.5 million in 2025, then rose by 3.55% to $16.0 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $16.0 million, $15.5 million, and $14.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.